Bristol Myers Squibb Company (NYSE:BMY - Get Free Report)'s stock price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $60.41 and traded as low as $59.48. Bristol Myers Squibb shares last traded at $59.4940, with a volume of 11,108,722 shares changing hands.
Trending Headlines about Bristol Myers Squibb
Here are a few of the latest headlines about BMY:
Analyst Upgrades and Downgrades
BMY has been the subject of several research analyst reports. The Goldman Sachs Group upgraded shares of Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 16th. Jefferies Financial Group restated a "buy" rating and set a $76.00 price target on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Argus raised Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price objective on the stock in a report on Wednesday, August 5th. HSBC reiterated a "hold" rating and issued a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. Finally, Citigroup reissued a "neutral" rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $65.46.
Read Our Latest Stock Analysis on BMY
Bristol Myers Squibb Price Performance
The firm has a market capitalization of $121.61 billion, a P/E ratio of 13.19, a PEG ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The company's 50 day moving average price is $61.65 and its 200 day moving average price is $60.41.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same quarter last year, the firm earned $1.63 EPS. The company's revenue for the quarter was up 6.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.46 EPS for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.88%.
Insider Activity
In other news, Director Julia A. Haller sold 3,800 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the transaction, the director owned 30,279 shares of the company's stock, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.05% of the company's stock.
Institutional Investors Weigh In On Bristol Myers Squibb
A number of large investors have recently bought and sold shares of BMY. Fi3 FINANCIAL ADVISORS LLC lifted its holdings in Bristol Myers Squibb by 177.6% during the third quarter. Fi3 FINANCIAL ADVISORS LLC now owns 11,283 shares of the biopharmaceutical company's stock worth $704,000 after acquiring an additional 7,219 shares during the period. Innovator Capital Management LLC bought a new position in Bristol Myers Squibb in the 3rd quarter worth about $7,083,000. Coastal Bridge Advisors LLC grew its stake in Bristol Myers Squibb by 63.5% during the third quarter. Coastal Bridge Advisors LLC now owns 92,833 shares of the biopharmaceutical company's stock valued at $5,793,000 after acquiring an additional 36,065 shares in the last quarter. Liontrust Investment Partners LLP purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at $80,000. Finally, Zacks Investment Management grew its position in Bristol Myers Squibb by 4.1% during the third quarter. Zacks Investment Management now owns 368,329 shares of the biopharmaceutical company's stock worth $22,984,000 after buying an additional 14,367 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.
Bristol Myers Squibb Company Profile
(
Get Free Report)
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.